Zacks Research Lowers Earnings Estimates for Haemonetics

Haemonetics Co. (NYSE:HAE) – Analysts at Zacks Research reduced their Q3 2026 EPS estimates for Haemonetics in a research note issued to investors on Wednesday, May 28th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings per share of $1.33 for the quarter, down from their previous forecast of $1.34. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2027 earnings at $1.46 EPS.

Other equities research analysts also recently issued research reports about the stock. Bank of America downgraded shares of Haemonetics from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $95.00 to $68.00 in a research report on Friday, February 7th. Raymond James reiterated a “strong-buy” rating and set a $105.00 target price (down from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Barrington Research decreased their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Needham & Company LLC decreased their target price on shares of Haemonetics from $104.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Finally, Wall Street Zen lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.89.

Haemonetics Price Performance

Shares of HAE opened at $69.66 on Monday. The company has a market capitalization of $3.35 billion, a P/E ratio of 27.43, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The firm has a 50 day moving average of $63.64 and a 200 day moving average of $69.92. Haemonetics has a twelve month low of $55.30 and a twelve month high of $94.99.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.02. The company had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.90 earnings per share.

Institutional Investors Weigh In On Haemonetics

Hedge funds have recently modified their holdings of the business. TD Waterhouse Canada Inc. bought a new stake in shares of Haemonetics during the 4th quarter valued at $25,000. Quarry LP grew its position in shares of Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 192 shares during the period. Covestor Ltd boosted its holdings in Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 439 shares during the period. Whittier Trust Co. bought a new position in Haemonetics in the 4th quarter worth $62,000. Finally, University of Texas Texas AM Investment Management Co. bought a new position in Haemonetics in the 1st quarter worth $65,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.